Achieving the promise of personalized medicine

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 401-405

  Reynolds, K S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; MERCAPTOPURINE; METHOTREXATE; TAMOXIFEN; WARFARIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BODY SIZE; BONE MARROW SUPPRESSION; DEMOGRAPHY; DRUG MONITORING; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH STATUS; HEREDITY; HOMOZYGOTE; HUMAN; INDIVIDUALIZATION; LIFESTYLE; LYMPHOBLASTOID CELL LINE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ACHIEVEMENT; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84866601265     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.147     Document Type: Review

References (22)

1. US Food and Drug Administration. News release: FDA approves Kalydeco to treat rare form of cystic fibrosis http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm289633.htm (31 January 2012).
2. Lesko, L.J. & Schmidt, S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin. Pharmacol. Ther. 92, 458-466 (2012).
3. Woodcock, J. & Lesko, L.J. Pharmacogenetics\tailoring treatment for the outliers. N. Engl. J. Med. 360, 811-813 (2009).
4. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
5. Relling, M.V., Hancock, M.L. & Rivera, G.K. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91, 2001-2008 (1999).
6. US Food and Drug Administration. The CDER Science Prioritization and Review Committee (SPaRC). Identifying CDER's Science and Research Needs Report http://www.fda.gov/downloads/drugs/scienceresearch/ucm264594.pdf (July 2011).
7. van der Greef, J., Hankemeier, T. & McBurney, R.N. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7, 1087-1094 (2006).
8. Crews, K.R., Hicks, J.K., Pui, C.-H., Relling, M.V. & Evans, W.E. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92, 467-475 (2012)
9. Völzke, H. et al. Population imaging as a valuable tool for personalized medicine. Clin. Pharmacol. Ther. 92, 422-424 (2012).
10. Cox, N.J., Gamazon, E.R., Wheeler, H.E. & Dolan, M.E. Clinical translation of cell-based pharmacogenomic discovery. Clin. Pharmacol. Ther. 92, 425-427 (2012).
11. Sadee, W. The relevance of "missing heritability" in pharmacogenomics. Clin. Pharmacol. Ther. 92, 428-430 (2012).
12. Lieb, W., Völzke, H., Pulley, J.M., Roden, D.M. & Kroemer, H.K. Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin. Pharmacol. Ther. 92, 443-445 (2012)
13. Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235-242 (2012).
14. He, Y.J. & McLeod, H.L. Ready when you are: easing into preemptive pharmacogenetics. Clin. Pharmacol. Ther. 92, 412-414 (2012).
15. O'Donnell, P.H. et al. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92, 446-449 (2012).
16. Johnson, J.A., Burkley, B.M., Langaee, T.Y., Clare-Salzler, M.J., Klein, T.E. & Altman, R.B. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92, 437-439 (2012).
17. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012).
18. Leeder, J.S. & Kearns, G.L. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin. Pharmacol. Ther. 92, 434-436 (2012).
19. Trenk, D., Zolk, O., Fromm, M.F., Neumann, F.-J. & Hochholzer, W. Personalizing antiplatelet therapy with clopidogrel. Clin. Pharmacol. Ther. 92, 476-485 (2012).
20. Binkhorst, L., van Gelder, T. & Mathijssen, R.H.J. Individualization of tamoxifen treatment for breast carcinoma. Clin. Pharmacol. Ther. 92, 431-433 (2012).
21. Keith, M.P., Edison, J.D. & Gilliland, W.R. Progress toward personalized treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 92, 440-442 (2012).
22. Lemmens, H.J.M. & Stanski, D.R. Individualized dosing with anesthetic agents. Clin. Pharmacol. Ther. 92, 417-419 (2012).